Brought to you by 
Inhale, Pfizer end inhaled insulin deal
Jan 1995
Executive Summary
Inhale Therapeutic Systems and Pfizer will collaborate to develop inhalable dry powder insulin products using Inhale's noninvasive pulmonary drug delivery system for macromolecules.
Deal Industry
-
Biotechnology
- Large Molecule
- Medical Devices
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Pulmonary
-
Drug Delivery
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- Includes Equity
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Inhale, Pfizer end inhaled insulin deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice